CureMatch

CureMatch is a precision medicine decision support platform designed for oncologists, cancer centers, NGS labs, concierge medicine providers, and their patients. The system uses advanced proprietary algorithms to calculate, rank, and score genomically matched combination cancer treatment options, delivering actionable insights tailored to each patient's unique cancer biology. Clinical evidence supports its value: progression-free survival was significantly improved in 75% of patients treated with combination therapies based on high CureMatch matching scores.

By processing genomic, proteomic, historical, and patient-specific data, CureMatch eliminates the days of manual research that would otherwise be required to evaluate the latest FDA-approved drug combinations. The platform produces a clear, structured report of ranked combination drug therapies targeting a patient's cancer at the genomic level, regardless of the diagnosed cancer type, empowering care teams to make well-informed treatment decisions quickly.

Core Capabilities

• Proprietary algorithms that calculate and rank personalized combination drug therapy options matched to each patient's genomic profile
• Extensive curation of genomic, historical, and patient-specific data to generate customized treatment scoring
• Analysis of targeted proteomics alongside genomic data, using FFPE tissue samples to provide a molecular-level profile of the patient's cancer
• Treatment matching that is cancer-type agnostic, focusing on the underlying genomic and molecular markers rather than the diagnosed cancer type
• Clear, actionable report layout designed for oncologists and care teams to support upcoming treatment decisions

Who CureMatch Serves

• Oncologists seeking predictive, evidence-based treatment analysis for individual patients
• Cancer treatment centers and NGS laboratories integrating precision medicine workflows
• Concierge medicine providers requiring personalized oncology insights
• BioPharma organizations and employers interested in precision oncology collaboration

Reimbursement and Regulatory Recognition

• CureMatch has been granted CPT Code 0794T by the American Medical Association, effective July 1, 2023
• The code covers a patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on tumor-specific cancer marker information from prior molecular pathology, immunohistochemical, or other pathology results
• Oncologists can use this Category III CPT code to submit claims to payers, enabling broader adoption of precision treatment matching and facilitating reimbursement for the CureMatch service

CureMatch operates in compliance with HIPAA requirements and maintains technology partnerships to support integration across the precision oncology ecosystem. The platform is grounded in peer-reviewed research, including the I-PREDICT study published in Nature Medicine (Kurzrock, 2019) and subsequent work published in MDPI Cancers (Kurzrock, 2020), validating the clinical benefit of molecularly matched combination therapies.